DOW JONES21,099.41-817.75 -3.73%
S&P 5002,480.18-104.41 -4.04%
NASDAQ7,393.79-306.31 -3.98%

Wedbush Upgrades Apellis Pharmaceuticals to Neutral, Announces $29 Price Target

Wedbush analyst Laura Chico upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Underperform to Neutral and announces $29 price target.

Benzinga · 03/11/2020 11:27

Wedbush analyst Laura Chico upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Underperform to Neutral and announces $29 price target.